141 related articles for article (PubMed ID: 38677269)
1. Dihydrotanshinone I inhibits gallbladder cancer growth by targeting the Keap1-Nrf2 signaling pathway and Nrf2 phosphorylation.
Li Z; Mo RL; Gong JF; Han L; Wang WF; Huang DK; Xu JG; Sun YJ; Chen S; Han GC; Sun DQ
Phytomedicine; 2024 Jul; 129():155661. PubMed ID: 38677269
[TBL] [Abstract][Full Text] [Related]
2. Dihydrotanshinone I inhibits ovarian tumor growth by activating oxidative stress through Keap1-mediated Nrf2 ubiquitination degradation.
Sun C; Han B; Zhai Y; Zhao H; Li X; Qian J; Hao X; Liu Q; Shen J; Kai G
Free Radic Biol Med; 2022 Feb; 180():220-235. PubMed ID: 35074488
[TBL] [Abstract][Full Text] [Related]
3. aPKCι promotes gallbladder cancer tumorigenesis and gemcitabine resistance by competing with Nrf2 for binding to Keap1.
Tian L; Lu Y; Yang T; Deng Z; Xu L; Yao W; Ma C; Li X; Zhang J; Liu Y; Wang J
Redox Biol; 2019 Apr; 22():101149. PubMed ID: 30822690
[TBL] [Abstract][Full Text] [Related]
4. 13-Acetoxysarcocrassolide Exhibits Cytotoxic Activity Against Oral Cancer Cells Through the Interruption of the Keap1/Nrf2/p62/SQSTM1 Pathway: The Need to Move Beyond Classical Concepts.
Liu YC; Peng BR; Hsu KC; El-Shazly M; Shih SP; Lin TE; Kuo FW; Chou YC; Lin HY; Lu MC
Mar Drugs; 2020 Jul; 18(8):. PubMed ID: 32718084
[TBL] [Abstract][Full Text] [Related]
5. Ethanol extract of Eclipta prostrata induces multiple myeloma ferroptosis via Keap1/Nrf2/HO-1 axis.
Li W; Yin X; Fu H; Liu J; Weng Z; Mao Q; Zhu L; Fang L; Zhang Z; Ding B; Tong H
Phytomedicine; 2024 Jun; 128():155401. PubMed ID: 38507850
[TBL] [Abstract][Full Text] [Related]
6. MDA-7/IL-24 inhibits Nrf2-mediated antioxidant response through activation of p38 pathway and inhibition of ERK pathway involved in cancer cell apoptosis.
Tian H; Zhang D; Gao Z; Li H; Zhang B; Zhang Q; Li L; Cheng Q; Pei D; Zheng J
Cancer Gene Ther; 2014 Oct; 21(10):416-26. PubMed ID: 25236495
[TBL] [Abstract][Full Text] [Related]
7. TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling.
Xu T; Yang Y; Chen Z; Wang J; Wang X; Zheng Y; Wang C; Wang Y; Zhu Z; Ding X; Zhou J; Li G; Zhang H; Zhang W; Wu Y; Song X
J Exp Clin Cancer Res; 2023 Aug; 42(1):190. PubMed ID: 37525222
[TBL] [Abstract][Full Text] [Related]
8. The discovery and characterization of K-563, a novel inhibitor of the Keap1/Nrf2 pathway produced by Streptomyces sp.
Hori R; Yamaguchi K; Sato H; Watanabe M; Tsutsumi K; Iwamoto S; Abe M; Onodera H; Nakamura S; Nakai R
Cancer Med; 2019 Mar; 8(3):1157-1168. PubMed ID: 30735010
[TBL] [Abstract][Full Text] [Related]
9.
Peng LY; An L; Sun NY; Ma Y; Zhang XW; Liu WH; Liu BL; Li P; Chen J
Am J Chin Med; 2019; 47(5):1113-1131. PubMed ID: 31352786
[TBL] [Abstract][Full Text] [Related]
10. Formononetin, a bioactive isoflavonoid constituent from Astragalus membranaceus (Fisch.) Bunge, ameliorates type 1 diabetes mellitus via activation of Keap1/Nrf2 signaling pathway: An integrated study supported by network pharmacology and experimental validation.
Chen H; Lou Y; Lin S; Tan X; Zheng Y; Yu H; Jiang R; Wei Y; Huang H; Qi X; Zhang R; Liu Z; Wu J
J Ethnopharmacol; 2024 Mar; 322():117576. PubMed ID: 38104880
[TBL] [Abstract][Full Text] [Related]
11. Esculetin induces antiproliferative and apoptotic response in pancreatic cancer cells by directly binding to KEAP1.
Arora R; Sawney S; Saini V; Steffi C; Tiwari M; Saluja D
Mol Cancer; 2016 Oct; 15(1):64. PubMed ID: 27756327
[TBL] [Abstract][Full Text] [Related]
12. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
[TBL] [Abstract][Full Text] [Related]
13. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer.
Shibata T; Kokubu A; Gotoh M; Ojima H; Ohta T; Yamamoto M; Hirohashi S
Gastroenterology; 2008 Oct; 135(4):1358-1368, 1368.e1-4. PubMed ID: 18692501
[TBL] [Abstract][Full Text] [Related]
14. Dihydrotanshinone I Inhibits Pancreatic Cancer Progression
Huang W; Dai Y; Xu L; Mao Y; Huang Z; Ji X
Curr Cancer Drug Targets; 2023; 23(9):731-741. PubMed ID: 37018533
[TBL] [Abstract][Full Text] [Related]
15. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis.
Roh JL; Kim EH; Jang H; Shin D
Redox Biol; 2017 Apr; 11():254-262. PubMed ID: 28012440
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen inhibits cell proliferation by impaired glucose metabolism in gallbladder cancer.
Huang S; Wang H; Chen W; Zhan M; Xu S; Huang X; Lin R; Shen H; Wang J
J Cell Mol Med; 2020 Jan; 24(2):1599-1613. PubMed ID: 31782270
[TBL] [Abstract][Full Text] [Related]
17. Icaritin activates Nrf2/Keap1 signaling to protect neuronal cells from oxidative stress.
Xu Y; Lu X; Zhang L; Wang L; Zhang G; Yao J; Sun C
Chem Biol Drug Des; 2021 Jan; 97(1):111-120. PubMed ID: 32654377
[TBL] [Abstract][Full Text] [Related]
18. EGFR-Targeted Immunotoxin Exerts Antitumor Effects on Esophageal Cancers by Increasing ROS Accumulation and Inducing Apoptosis via Inhibition of the Nrf2-Keap1 Pathway.
Yang Y; Tian Z; Ding Y; Li X; Zhang Z; Yang L; Zhao F; Ren F; Guo R
J Immunol Res; 2018; 2018():1090287. PubMed ID: 30596104
[TBL] [Abstract][Full Text] [Related]
19. Identification of dihydrotanshinone I as an ERp57 inhibitor with anti-breast cancer properties via the UPR pathway.
Shi W; Han H; Zou J; Zhang Y; Li H; Zhou H; Cui G
Biochem Pharmacol; 2021 Aug; 190():114637. PubMed ID: 34062127
[TBL] [Abstract][Full Text] [Related]
20. A Novel Nrf2 Pathway Inhibitor Sensitizes Keap1-Mutant Lung Cancer Cells to Chemotherapy.
Zhang D; Hou Z; Aldrich KE; Lockwood L; Odom AL; Liby KT
Mol Cancer Ther; 2021 Sep; 20(9):1692-1701. PubMed ID: 34158350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
